Hims & Hers Health, Inc. (HIMS) vs Regencell Bioscience Holdings Limited (RGC)
- Hims & Hers Health, Inc. HIMS 28.07 −4.46%
- Regencell Bioscience Holdings Limited RGC 9.59 +0.74%
Hims & Hers Health, Inc. and Regencell Bioscience Holdings Limited are both Drug Manufacturers Specialty & Generic companies. Hims & Hers Health, Inc. is the larger, with a market value of $6.9B against $4.7B — 1.5× the size. Regencell Bioscience Holdings Limited has the higher net margin (0.00% vs −5.51%) and the higher return on invested capital (0.00% vs −11.4%). Across the 11 metrics below, Regencell Bioscience Holdings Limited leads on 7 and Hims & Hers Health, Inc. on 4.
Valuation
Profitability
| Metric | HIMS | RGC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 68.43% | — | 53.94% |
| Operating margin | (5.99%) | — | 0.00% |
| Net margin | (5.51%) | 0.00% | 0.00% |
| Free cash flow margin | 3.22% | 0.00% | 0.00% |
| Return on equity | (32.03%) | 0.00% | (0.40%) |
| Return on assets | (5.16%) | 0.00% | (3.32%) |
| Return on invested capital | (11.38%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack